- Home
- IVA vs ATLC Comparison
IVA vs ATLC Comparison
Compare IVA & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- ATLC
- Stock Information
- Founded
- IVA 2011
- ATLC 1996
- Country
- IVA France
- ATLC United States
- Employees
- IVA N/A
- ATLC N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- ATLC Finance: Consumer Services
- Sector
- IVA Health Care
- ATLC Finance
- Exchange
- IVA Nasdaq
- ATLC Nasdaq
- Market Cap
- IVA 769.0M
- ATLC 900.3M
- IPO Year
- IVA 2020
- ATLC 1999
- Fundamental
- Price
- IVA $6.24
- ATLC $54.14
- Analyst Decision
- IVA Strong Buy
- ATLC Buy
- Analyst Count
- IVA 7
- ATLC 7
- Target Price
- IVA $16.00
- ATLC $78.71
- AVG Volume (30 Days)
- IVA 61.2K
- ATLC 81.9K
- Earning Date
- IVA 09-29-2025
- ATLC 11-06-2025
- Dividend Yield
- IVA N/A
- ATLC N/A
- EPS Growth
- IVA N/A
- ATLC 35.13
- EPS
- IVA N/A
- ATLC 5.69
- Revenue
- IVA $19,929,536.00
- ATLC $457,158,000.00
- Revenue This Year
- IVA N/A
- ATLC $327.06
- Revenue Next Year
- IVA N/A
- ATLC $18.03
- P/E Ratio
- IVA N/A
- ATLC $9.51
- Revenue Growth
- IVA N/A
- ATLC 26.20
- 52 Week Low
- IVA $1.60
- ATLC $34.15
- 52 Week High
- IVA $6.55
- ATLC $78.91
- Technical
- Relative Strength Index (RSI)
- IVA 60.61
- ATLC 26.18
- Support Level
- IVA $5.59
- ATLC $57.01
- Resistance Level
- IVA $6.55
- ATLC $74.83
- Average True Range (ATR)
- IVA 0.33
- ATLC 3.00
- MACD
- IVA 0.01
- ATLC -1.93
- Stochastic Oscillator
- IVA 78.02
- ATLC 1.17
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.